Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt. Limited' to contract produce pharmaceutical products for export market. Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility. Ferron Lifecare Private Limited, incorporated on 30th January 2020 was promoted by Dr. Ashish Sakalkar and Mr. Sachin Badakh. Finally, 'Asston Pharmaceuticals Private Limited' was converted from a Private Limited into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products.
Company is engaged in th ...e manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. It operates under brand 'Asston'. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.
Company's operations are supported by experienced founders with expertise in managing supply chains and maintaining product quality.
Currently, Company has its production plant at Ambernath, Maharashtra, for producing generic medicines in the tablet form and nutraceutical medicines in the tablet form, syrup and sachet form. Facility has total production capacity of up to around 8-9 crore tablets per month. Further, it produces an average of 5-6 crore tablets per month, with production capacity varying based on the weight of medicines. Higherweight medicines result in lower production quantities and vice versa. The syrup production capacity for nutraceuticals is approximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, depending on the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and central FDA authorities. Company engages contract manufacturers to produce generic medicines and antibiotics in various forms, including tablets, sachets, syrups, and capsules.
Company is planning an Initial Public Issue of 22,41,600 Equity Shares of face value of Rs. 10/- through Fresh Issue.
1. Can I buy Asston Pharmaceuticals Ltd from PL Capital? ›
Yes, you can invest in Asston Pharmaceuticals Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Asston Pharmaceuticals Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Asston Pharmaceuticals Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.
2. Does Asston Pharmaceuticals Ltd pay dividends? ›
Asston Pharmaceuticals Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.
3. What is the current share price of Asston Pharmaceuticals Ltd ? ›
As of
06-11-2025 the share price for Asston Pharmaceuticals Ltd. is 80 on the NSE (Note: Prices are dynamic and update frequently during market hours).
4. What is the 52-week high and low of Asston Pharmaceuticals Ltd ? ›
The 52-week high and low of Asston Pharmaceuticals Ltd share price is ₹ 80 - ₹ 126 as of
06-11-2025 .
PL Ringside View
Our fireside chat series where industry experts and top management share valuable insights for our clients
